Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study
Thomas Yau, Ahmed Kaseb, Ann Lii Cheng, Shukui Qin, Andrew X. Zhu, Stephen L. Chan, Tamar Melkadze, Wattana Sukeepaisarnjaroen, Valery Breder, Gontran Verset, Edward Gane, Ivan Borbath, Jose David Gomez Rangel, Baek Yeol Ryoo, Tamta Makharadze, Philippe Merle, Fawzi Benzaghou, Steven Milwee, Zhong Wang, Dominic CurranRobin Kate Kelley, Lorenza Rimassa
Dive into the research topics of 'Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study'. Together they form a unique fingerprint.